SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Russian Bear who wrote (16135)3/1/1998 8:49:00 AM
From: Alper H.YUKSEL  Read Replies (3) | Respond to of 32384
 
''These studies will be used to support our NDA filing for
Panretin(TM) Gel in AIDS-related KS in March.''

Another confirmation of the NDA filing slated for this quarter. Based on the broad range of trials and the efficacy and safety profile demonstrated in those trials, I can not see how the NDA could fail.

Still, I don't believe today's news will take us any higher.

Regards
Alper



To: Russian Bear who wrote (16135)3/1/1998 12:55:00 PM
From: Andreas Helke  Respond to of 32384
 
With this press release about already known phase I and II trial results I have the impression that Ligand is trying to increase its share price. This would make sense when trying to get an optimal deal with Eli Lilly's equity investment after choosing to opt for a royalty increase instead of marketing a Lilly compound.
For me the most interesting part of the press release was the sentence that stated that the Panretin NDA was still on track for march.

Andreas



To: Russian Bear who wrote (16135)3/1/1998 3:33:00 PM
From: Mudcat  Read Replies (1) | Respond to of 32384
 
Henry:

Could you explain these Phase 1/2 studies. The announcement stated "Complete or partial response was seen in 27% of Panretin treated lesions." Is this considered good? If I was taking a drug I would hope there was a better than 27% chance of seeing some response.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News